Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44156   clinical trials with a EudraCT protocol, of which   7326   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-006413-11
    Sponsor's Protocol Code Number:CDX0159-06
    National Competent Authority:Germany - PEI
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-04-21
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - PEI
    A.2EudraCT number2021-006413-11
    A.3Full title of the trial
    A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Spontaneous Urticaria
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    To be completed
    A.4.1Sponsor's protocol code numberCDX0159-06
    A.5.4Other Identifiers
    Name:INDNumber:140159
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCelldex Therapeutics
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCelldex Therapeutics, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCelldex Therapeutics, Inc.
    B.5.2Functional name of contact pointElsa Paradise
    B.5.3 Address:
    B.5.3.1Street Address160 Gould Street Suite 202
    B.5.3.2Town/ cityNeedham
    B.5.3.3Post code02494
    B.5.3.4CountryUnited States
    B.5.4Telephone number17814654940
    B.5.5Fax number12032081533
    B.5.6E-maileparadise@celldex.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namebarzolvolimab
    D.3.2Product code CDX-0159
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCDX-0159
    D.3.9.1CAS number 2438203-51-9
    D.3.9.2Current sponsor codeCDX-0159
    D.3.9.3Other descriptive nameHumanised IgG1k monoclonal antibody against KIT
    D.3.9.4EV Substance CodeSUB219179
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Spontaneous Urticaria
    E.1.1.1Medical condition in easily understood language
    Long-lasting hives with an unknown cause
    E.1.1.2Therapeutic area Diseases [C] - Skin and Connective Tissue Diseases [C17]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10009159
    E.1.2Term Chronic urticaria
    E.1.2System Organ Class 10040785 - Skin and subcutaneous tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    •To evaluate efficacy of different dose regimens of CDX-0159, compared to placebo, in reducing urticaria activity as assessed by urticaria activity score (UAS) in patients with CSU refractory to H1AH therapy
    E.2.2Secondary objectives of the trial
    •To evaluate the efficacy of different dose regimens of CDX-0159, compared to placebo, in reducing itch severity as assessed by itch severity score (ISS) in CSU patients
    •To evaluate the efficacy of different dose regimens of CDX-0159, compared to placebo, in reducing hive severity as assessed by hive severity score (HSS) in CSU patients
    •To evaluate the efficacy of different dose regimens of CDX-0159, compared to placebo, in reducing angioedema severity as assessed by angioedema activity score (AAS) in CSU patients
    •To evaluate the long-term (up to 52 weeks) efficacy of different dose regimens of CDX-0159 in CSU patients
    •To evaluate the safety profile of different dose regimens of CDX-0159, compared to placebo, in CSU patients
    •To evaluate the long-term (up to 52 weeks) safety profile of different dose regimens of CDX-0159 in CSU patients
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Additional PK/tryptase samples are being taken in U.S., Germany, and South Africa (optional particpation). For this CTA, this would apply to Germany.
    E.3Principal inclusion criteria
    1.Read, understood, and provided written informed consent, and Health Insurance Portability and Accountability Act (HIPAA) authorization if applicable, after the nature of the study has been fully explained.
    2.Male or female, ≥ 18 years of age at the time of signing the informed consent
    3.Diagnosis of CSU ≥ 6 months prior to Screening Visit 1
    4.CSU refractory to a stable regimen of second-generation non-sedating H1AH as defined by all of the following:
    •Recurrent pruritic wheals with or without angioedema for ≥ 6 weeks at any time prior to Screening Visit 1 despite treatment with a H1AH
    Note: Hives consistent with CSU should be documented and confirmed by the investigator prior to randomization
    •Patients must have been on a stable regimen of daily use of a second-generation non-sedating H1AH at approved or increased (up to 4 times the approved) dose for the treatment of CSU for ≥ 4 weeks prior to randomization and which is expected to remain stable at the time of randomization and throughout the study
    •Weekly urticaria activity score (UAS7, range: 0-42) ≥ 16 and weekly itch severity score (ISS7, range: 0-21) ≥ 8 during the 7-day period immediately prior to randomization
    5.Hemoglobin, white blood count (WBC), absolute neutrophil count (ANC), and platelets ≥ the lower limit of normal (LLN) and ≤ than 1.5 X the upper limit of normal (ULN) range if the values between ULN and 1.5X ULN are deemed to be not clinically significant by the Investigator, at Screening Visits 1 and 2*
    6.Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2 x ULN (unless elevated bilirubin is related to
    Gilbert's Syndrome), and total bilirubin ≤ ULN, at Screening Visits 1 and 2*.
    *For 5 and 6 above, if test results do not meet the above criteria, a repeat test may be performed to establish eligibility.
    7.Females must meet one of the following criteria:
    If of childbearing potential, agree to use highly effective contraception from the time of Screening Visit 1 and for at least 150 days after receipt of study treatment. Highly effective methods of contraception include the following:
    •combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, administered as oral, intravaginal or transdermal
    •progestogen-only hormonal contraception associated with inhibition of ovulation administered as oral, injectable or by implantable means
    •intrauterine device (IUD)
    •intrauterine hormone-releasing system (IUS)
    Females of non-childbearing potential, who are surgically sterile (i.e., had undergone complete hysterectomy, salpingectomy and bilateral oophorectomy) or in a menopausal state (at least 1 year without menses), as confirmed by FSH levels, are eligible.
    8.Male patients must agree that while participating in the study and for at least 150 days after receipt of the study treatment, they will use highly effective methods of contraception with female partners of childbearing potential, and they will not donate sperm. Vasectomy is considered to be a highly effective method of contraception provided that the vasectomized patient has received medical assessment confirming surgical success.
    9.Willing and able to comply with all study requirements and procedures, including the completion of a daily symptom diary during screening and throughout the study. Note: For study eligibility, patients need to complete the diary for at least 6 of 7 days immediately prior to randomization.
    E.4Principal exclusion criteria
    1.Diseases with possible symptoms of urticaria or angioedema such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), autoimmune syndromes with urticarial lesions (e.g., Schnitzler Syndrome) and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency).
    2.Active chronic inducible urticaria (CIndU) including symptomatic dermographism (urticaria factitia), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria that would confound CSU assessments based on the investigator’s clinical judgment.
    3.Any other active pruritic skin diseases that would confound CSU assessments (e.g., atopic dermatitis, psoriasis, bullous pemphigoid, dermatitis herpetiformis, prurigo nodularis, chronic pruritus of unknown origin) based on the investigator's clinical judgment
    4.Regular (3 or more days a week) use of topical corticosteroid, topical calcineurin inhibitors or topical antihistamines, first-generation sedating antihistamines (e.g., diphenhydramine, hydroxyzine, doxylamine) and other sedatives/hypnotics (e.g., doxepin), within 1 week of Screening Visit 1.
    5.Phototherapy with ultraviolet (UV) A or UVB within 4 weeks of Screening Visit 1.
    6.Non-biologic systemic (oral or injectable) agents listed below, including investigational agents, within 4 weeks or 5 half-lives, whichever is longer, prior to Screening Visit 1.
    Note: Non-biologic systemic (oral or injectable) agents: corticosteroids, non-steroidal immunosuppressants (e.g., methotrexate, cyclosporin, tacrolimus, mycophenolate mofetil, azathioprine, cyclophosphamide), and other immunomodulators (e.g., dapsone, sulfasalazine, hydroxychloroquine, and colchicine, Jak inhibitors, Bruton's kinase [BTK] inhibitors), anticoagulants (e.g., warfarin), antifibrinolytic agents (e.g., tranexamic acid), mast cell stabilizers (e.g., cromolyn, ketotifen), and other investigational agents
    7.Biologic therapy including approved or investigational biologic agents (e.g., omalizumab, ligelizumab, dupilumab, interleukin (IL)-1 inhibitor, tumor necrosis factor (TNF) inhibitor, B-cell depleting therapy (e.g., rituximab), or other investigational monoclonal antibodies, intravenous immunoglobulin (IVIG) therapy or plasmapheresis within 3 months prior to Screening Visit 1.
    8.Receipt of a live vaccine within 2 months prior to the Baseline (Day 1) Visit (patients must agree to avoid live vaccination during study treatment and within 3 months thereafter).
    Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally inactivated virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Currently authorized COVID-19 vaccines are allowed.
    9.Planned or anticipated use of any prohibited medications during screening and study treatment, and follow-up.
    10.Diagnosis of idiopathic anaphylaxis or a history of anaphylaxes (such as those due to Hymenoptera venom or IgE-mediated food allergy), that in the opinion of the investigator, could increase the patient’s risk for systemic hypersensitivity reactions; or any known contraindications or hypersensitivity to any component of study treatments, drugs of similar chemical classes (i.e., to murine, chimeric or human antibodies) or antihistamines.
    11.Women who are pregnant or nursing. All female patients with reproductive potential must have a negative pregnancy test prior to starting study treatment.
    12.Severe or uncontrolled chronic diseases (e.g., chronic hepatic or renal disease, diabetes mellitus) that might interfere with the evaluation of the clinical effect or safety of study treatment.
    13. Patients with moderate-to-severe pulmonary or cardiovascular
    diseases, see Appendix 10 for guidelines.
    Note: patients with symptomatic cardiovascular or pulmonary disease
    that requires medication should be carefully assessed and discussed
    with the medical monitor to assure their cardiovascular and/or
    pulmonary status does not increase their risk of study participation.
    14. Patients with contraindications for use of epinephrine (e.g., history
    of closed angle glaucoma, significant arrhythmias, myocardial infarction,
    or cardiomyopathy) or are taking medications that might interfere with
    pharmacodynamic actions of epinephrine (e.g., beta blockers).
    15.Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.
    16.Patients with active COVID-19 infection.
    17.History of malignancy within 5 years before Screening Visit 1, except fully treated carcinoma in-situ of the cervix, fully treated and resolved non-metastatic squamous or basal cell carcinoma of the skin

    More criteria can be found in Synopsis (18 to 24)
    E.5 End points
    E.5.1Primary end point(s)
    Mean change from baseline to Week 12 in UAS7
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 12 in UAS7
    E.5.2Secondary end point(s)
    - Mean change from baseline to Week 12 for ISS7, HSS7, and AAS7.
    - Safety as assessed by adverse events over the treatment periods to Week 16 and Week 52.
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Mean change from baseline to Week 12 for ISS7, HSS7, and AAS7.
    - Safety as assessed by adverse events over the treatment periods to Week 16 and Week 52.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned14
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA75
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Georgia
    South Africa
    United States
    Belgium
    Bulgaria
    Estonia
    Germany
    Hungary
    Poland
    Spain
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months7
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 150
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 18
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state44
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 116
    F.4.2.2In the whole clinical trial 180
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Hospital standard of care.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-07-26
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-07-27
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA